Impact of the Frequency of My Dose CoachTM Use on Clinical Outcomes in Type 2 Diabetes
![](/.imaging/webp/sanofi-templates/article-hero-w768/dam/campus-sanofi-sa/new/patient-support/hero/mdc-banner-gradient.webp/jcr:content/mdc-banner-gradient.webp)
Objectives
To compare the efficacy in achieving the fasting self-monitoring plasma glucose (SMPG) Target of 90-130 mg/dL, between two insulin glargine titration methods: My Dose CoachTM app with remote real-time settings (MDC) and conventional strategy (CS) with face-to- face insulin dose modifications every 2 weeks.
![](/.imaging/webp/sanofi-templates/w1080/dam/campus-sanofi-sa/new/patient-support/images/mdc-use.png/jcr:content/mdc-use.png)
In this analysis of the impact of My Dose CoachTM use…
![](/.imaging/webp/sanofi-templates/w1080/dam/campus-sanofi-sa/new/patient-support/images/mdc-digital.png/jcr:content/mdc-digital.png)
Executive Summary
Results
A) Proportion of My Dose CoachTM users
achieving FBG target
![](/dam/jcr:732c3415-3483-4d41-92b4-1a516cc63f2b/graph-1.jpg)
B) Time to FBG target achievement
![](/dam/jcr:6c5c72b1-bc50-475a-96a0-43749c038c26/graph-2.jpg)
C) FBG change, in different app usage
frequency groups
![](/dam/jcr:55d49272-623f-44e1-ad2c-68f523db6d8e/graph-3.jpg)
Conclusion
Higher My Dose CoachTM usage was associated with:
Better FBG target achievement
Shorter time to FBG target
Greater reduction from baseline FBG
Hypoglycemia risk did not change with increased frequency of My Dose CoachTM usage
- People with T2D initiating BI using My Dose CoachTM >3 days/ week during titration had better glycemic outcomes than those with lower usage, with no increase in hypoglycemia
- These results suggest that use of My Dose CoachTM may help people with T2D manage their disease by appropriately titrating their BI dose to achieve glycemic targets; such a personal application may also encourage patient participation in managing their condition
Method
- This retrospective observational cohort analysis included people with T2D who were registered for My Dose CoachTM by their HCP between 8/1/2018 – 4/30/2020 and received BI
- Study outcomes included change in FBG, change in insulin dose, occurrence of hypoglycemia (defined as FBG below the HCP defined hypoglycemia cut-off per the titration plan), usage of My Dose CoachTM, percentage of users achieving FBG target, and time to achieving FBG target
- Users were trained to record FBG and administered BI doses directly in My Dose CoachTM. Users with an activated care plan and ≥ 2 FBG observations spanning at least 2 weeks (active users) were selected for analysis
- Users who logged ≥ 3 consecutive FBG measurements within their prescribed target range were defined as reaching titration target (specified by the HCP during care plan creation)
Reference
- Poster 392, ATTD 5–2 2021 June Virtual Meeting, M.A. POLANCO et al
![](/dam/jcr:7abe7423-c549-49c9-b5ce-a8f991eaa54e/mdc-logo.jpg)
My Dose Coach is not intended to replace the care or advice of a healthcare team
My Dose Coach is approved in Saudi Arabia under authorization number: GHTF-2020-2084